Revenue growth accelerates; adjusted EBITDA positive for third consecutive quarter.
Evolus reported Q2 2026 results on August 5, 2026, delivering revenue growth that beat guidance and marking the third consecutive quarter of positive adjusted EBITDA. The company raised its full-year 2026 financial outlook, signaling sustained momentum in Jeuveau adoption and market share gains.
For medspa owners, Evolus's profitability and guidance raise matter because a financially healthy competitor with cash flow can invest in rebate programs, direct sales to aesthetics practices, and brand-building—exactly what the material event filing suggests is underway. Evolus Rewards is now backed by a company with runway to sustain aggressive pricing.
Revenue growth accelerates; adjusted EBITDA positive for third consecutive quarter.
The revenue growth acceleration (21% YoY per earnings highlights) reflects both toxin volume and the company's shift toward medspas and aesthetic clinics. If Jeuveau is gaining share in your market, your Botox volume may be under pressure. Monitor your Botox patient retention and consider whether Evolus Rewards economics justify a trial order to test patient acceptance.
Source: original report ↗
Frequently asked questions
Is Evolus Jeuveau profitable and how does that affect medspa pricing?
Yes—Evolus posted its third consecutive quarter of positive adjusted EBITDA in Q2 2026 and raised its full-year outlook. A profitable Evolus can now sustain aggressive rebate programs and direct sales incentives to aesthetics practices, which may pressure your Botox margins if you haven't evaluated Jeuveau alternatives.
What is Jeuveau's market share growth compared to Botox?
Evolus reported 21% year-over-year revenue growth in Q2 2026, driven by both toxin volume and a deliberate shift toward medspas and aesthetic clinics. While Evolus doesn't break out exact market share, the acceleration signals meaningful gains in the aesthetics channel where your Botox patient base may be vulnerable.
Should medspa owners offer Jeuveau or stick with Botox?
Monitor your Botox patient retention closely—if Jeuveau is gaining traction in your market, your volume may face pressure. Consider a trial order of Jeuveau through Evolus Rewards to test patient acceptance and compare economics; a financially healthy competitor with cash flow can sustain pricing advantages longer than a struggling one.
What is Evolus Rewards and is it worth joining?
Evolus Rewards is Evolus's rebate and incentive program for aesthetics practices, now backed by a company with positive cash flow and the runway to sustain aggressive pricing. Evaluate whether the rebate economics justify a trial to retain patients who might otherwise switch to Jeuveau-offering competitors.
How much did Evolus revenue grow in Q2 2026?
Evolus delivered 21% year-over-year revenue growth in Q2 2026, beating its own guidance and marking the third straight quarter of positive adjusted EBITDA. The company also raised its full-year 2026 outlook, signaling sustained momentum in Jeuveau adoption across medspas and aesthetic clinics.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
